Safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1893 in patients with obstructive hypertrophic cardiomyopathy: a randomized, double-blind, placebo-controlled phase 1 trial (ESC-WCC 2025) - May 15, 2025 - Pres time: Aug 29, 2025; 01:25 PM - 01:35 PM; Location: Science Box 4(Research Gateway); Online; "Conclusion HRS-1893 demonstrated favourable safety and PK profiles. It rapidly and effectively reduced resting and Valsalva LVOT-G, while keeping LVEF within the safety limits, providing a novel treatment option for patients with obstruction HCM."
Clinical • P1 data • PK/PD data • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy
|
|
L Kang1; X Wu1; K Zhang1; Z Zhu1; X Quan1; Q Wei1; Y Xia1; X Li1; X Zhang1; Z Wang1; L Xu1; D Wang1; W Jiang1; L Wang1; L Song1
|